This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
The efficacy of anti–PD-1 treatment was enhanced by deletion of Pcsk9 or PCSK9 inhibition in mice.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2021
Volume 11, Issue 1
Volume 11, Issue 1
PCSK9 Causes MHC Class I Lysosomal Degradation to Promote Tumor Growth
Jump to section
Advertisement